Protagonist Therapeutics announced new data from the icotrokinra ICONIC-TOTAL study, presented at the Society for Investigative Dermatology Annual Meeting. The data highlighted efficacy in difficult-to-treat areas of psoriasis.
Results showed that 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16. This demonstrates icotrokinra's ability to provide significant skin clearance in challenging anatomical regions.
The company also presented preclinical data on PN-881, an oral peptide IL-17 antagonist, at the same meeting. This further illustrates Protagonist's ongoing commitment to advancing its pipeline and leveraging its peptide technology platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.